These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24176826)

  • 1. Complications associated with oral anticoagulation therapy.
    Howard PK
    Adv Emerg Nurs J; 2013; 35(4):283-6. PubMed ID: 24176826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Healey JS; Eikelboom J; Douketis J; Wallentin L; Oldgren J; Yang S; Themeles E; Heidbuchel H; Avezum A; Reilly P; Connolly SJ; Yusuf S; Ezekowitz M;
    Circulation; 2012 Jul; 126(3):343-8. PubMed ID: 22700854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation, novel agents, and procedures: can we pardon the interruption?
    Garcia DA; Granger CB
    Circulation; 2012 Jul; 126(3):255-7. PubMed ID: 22700855
    [No Abstract]   [Full Text] [Related]  

  • 4. Managing new oral anticoagulants in the perioperative and intensive care unit setting.
    Levy JH; Faraoni D; Spring JL; Douketis JD; Samama CM
    Anesthesiology; 2013 Jun; 118(6):1466-74. PubMed ID: 23416382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
    Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complications of anticoagulation.
    Bilen O; Teruya J
    Dis Mon; 2012 Aug; 58(8):440-7. PubMed ID: 22818558
    [No Abstract]   [Full Text] [Related]  

  • 7. Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
    Alonso-Coello P; Zhou Q; Guyatt G
    Thromb Haemost; 2012 Oct; 108(4):647-53. PubMed ID: 22918481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
    Nagarakanti R; Ezekowitz MD; Oldgren J; Yang S; Chernick M; Aikens TH; Flaker G; Brugada J; Kamensky G; Parekh A; Reilly PA; Yusuf S; Connolly SJ
    Circulation; 2011 Jan; 123(2):131-6. PubMed ID: 21200007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
    Pfeilschifter W; Luger S; Brunkhorst R; Lindhoff-Last E; Foerch C
    Cerebrovasc Dis; 2013; 36(2):115-9. PubMed ID: 24029592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants.
    Rockey DC
    Nat Rev Gastroenterol Hepatol; 2015 Mar; 12(3):131-2. PubMed ID: 25601661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention and treatment of major bleeding during anticoagulation].
    Yasaka M; Okada Y
    Rinsho Shinkeigaku; 2013; 53(11):997-9. PubMed ID: 24291858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran and mechanical valves: less effective and more risky than warfarin.
    Prescrire Int; 2013 May; 22(138):128. PubMed ID: 23819180
    [No Abstract]   [Full Text] [Related]  

  • 13. The importance of postapproval data for dabigatran.
    Redberg RF
    JAMA Intern Med; 2015 Jan; 175(1):25. PubMed ID: 25365377
    [No Abstract]   [Full Text] [Related]  

  • 14. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran: uncharted waters and potential harms.
    Radecki RP
    Ann Intern Med; 2012 Jul; 157(1):66-8. PubMed ID: 22751762
    [No Abstract]   [Full Text] [Related]  

  • 16. Dabigatran and postmarketing reports of bleeding.
    Southworth MR; Reichman ME; Unger EF
    N Engl J Med; 2013 Apr; 368(14):1272-4. PubMed ID: 23484796
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".
    Hjemdahl P; Johnsson H; Wallén NH
    Circulation; 2013 Mar; 127(11):e505. PubMed ID: 23509038
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".
    David JS; Piriou V; Albaladejo P
    Circulation; 2013 Mar; 127(11):e504. PubMed ID: 23509037
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.
    Healey JS; Eikelboom J; Yang S; Themeles E; Connolly SJ; Yusuf S; Douketis J; Wallentin L; Oldgren J; Heidbuchel H; Avezum A; Reilly P; Ezekowitz M
    Circulation; 2013 Mar; 127(11):e506. PubMed ID: 23646374
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.